

Department of Planning and Budget

2023 Fiscal Impact Statement

1. Bill Number: HB2274

House of Origin	<input type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input checked="" type="checkbox"/> Enrolled

2. Patron: Kilgore

3. Committee: Passed both Houses.

4. Title: Pharmacist scope of practice; initiation of treatment for certain diseases and conditions.

5. Summary: Allows pharmacists to initiate treatment with, dispense, or administer controlled substances or devices for the initiation of treatment of group A streptococcus bacteria infection, influenza virus infection, COVID-19 virus infection, and urinary tract infection to persons 18 years of age or older with whom the pharmacist has a bona fide pharmacist-patient relationship in accordance with regulations set forth by the Board of Pharmacy. The bill directs the Board of Pharmacy shall adopt a statewide protocol for the initiation of treatment with and dispensing and administering of drugs and devices by pharmacists in accordance with § 54.1-3303.1 of the Code of Virginia, as amended by this act, by November 1, 2023. Such protocol shall be developed by a work group consisting of representatives from the Board of Pharmacy, the Board of Medicine, and the Department of Health. The work group shall have an equal number of members who are representatives of the Board of Pharmacy and the Board of Medicine.

6. Budget Amendment Necessary: No.

7. Fiscal Impact Estimates: Final.

8. Fiscal Implications: This legislation would not have a fiscal impact on the Virginia Department of Health or the Department of Health Professions.

9. Specific Agency or Political Subdivisions Affected: None.

10. Technical Amendment Necessary: No.

11. Other Comments: None.